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The challenges to vaccine biology are dramatized by the
current situation with an AIDS vaccine (see Letvin, this
Perspective series, ref. 1). For years, data have been available on the HIV-1 genome and its proteins, as well as
numerous antigens recognized by the immune system.
Still, this information has not been readily translated
into candidate vaccines that induce the broad and longlasting T cell–mediated immunity thought to be necessary to protect people from acquiring AIDS (2–5). Vaccines are also lacking for many other serious infections
in which T cell–mediated immunity should be protective. These include pathogens whose genomic sequences
and antigenic proteins are well characterized: tuberculosis, malaria, and the herpes simplex, papilloma,
Epstein-Barr, and hepatitis C viruses. In essence, the
identification of foreign antigens is necessary but not
sufficient for producing vaccines that are effective in the
T cell sphere. Better vaccine delivery and vaccine adjuvants, or enhancers of immunity, are required (6, 7).
We propose that dendritic cell (DC) physiology
should be considered and exploited in meeting each of
the challenges in vaccine biology that lie ahead (see
Table 1). DCs act as nature’s adjuvants for regulating
antigen-specific immunity. As antigen-presenting cells,
DCs capture antigens, process them into peptides, and
present them on products of the MHC to T cells. DCs
are both efficient and specialized in antigen presentation, and they control the magnitude, quality, and
memory of the ensuing immune response. DCs have
been used successfully as cellular adjuvants in mice to
elicit protective T cell–mediated immunity against
pathogens and tumors (8, 9). These cells are now being
used to prime and expand T cells specific for human
cancers (refs. 10–12; see also Yu and Restifo, this Perspective series, ref. 13). The responding T cells include
helper cells, especially Th1 CD4+ cells, which produce
IFN-γ; and killer cells, especially CD8+ cytolytic T lymphocytes (CTLs), which exocytose granules rich in perforin and granzyme. New information indicates that
DCs control responses by other classes of lymphocytes
(B, NK, and NKT cells) and elicit T cell memory, a critical goal of vaccination.
Developing the capacity to harness DCs for vaccination seems particularly urgent in confronting infectious
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agents that, like HIV-1, pose unusual demands with
respect to safety; the time-honored approach of microbial attenuation is now being set aside as vaccine biologists turn to defined antigens, poorly replicating vectors, and DNA. Although these vaccines introduce
foreign microbial products, they often generate weak
immunity, especially T cell–mediated immunity. Consequently, greater emphasis on underlying immunologic processes is needed, notably the strong adjuvant
roles of DCs. Interestingly, as we discuss below, even the
classical vaccine approach of microbial attenuation,
used successfully for smallpox and measles, may have
unknowingly exploited the adjuvant roles of DCs.

DCs as natural adjuvants
In vitro studies. DCs are potent stimulators of T cell
responses and T-dependent antibody formation in tissue culture. Relatively few DCs and relatively low doses
of antigen are required to elicit high levels of lymphocyte proliferation and differentiation. Initially, because
DCs had to be isolated directly from lymphoid tissues
(or, in the case of humans, from blood), the scarcity of
these cells imposed a serious limitation on DC research.
Typically, DCs make up less than 1% of a given cell population — a figure that is somewhat misleading since the
frequency of these cells is at least 100 times greater than
that of T cells specific for any given antigen. Moreover,
DCs are extensively ramified in regions of the lymph
nodes through which T cells recirculate (Figure 1).
Most investigators now study DCs produced in much
larger numbers from either CD34+ proliferating progenitors or CD14+ nonproliferating monocytic precursors. These DCs are charged or “pulsed” with antigens,
which they efficiently process and display as MHC-peptide complexes. Antigen-pulsed DCs can be placed into
culture with lymphocytes, whereupon T cells begin to
proliferate and to produce lymphokines and various
cytotoxic molecules. Primary responses to microbial
antigens can be difficult to achieve in short-term (1
week) culture, because the initial number of antigenresponsive cells is so low (<1 in 105 lymphocytes), but
mature DCs rapidly induce recall responses to many
antigens, including those from HIV-1 and influenza.
These viral antigens are presented to primed CD4+ and
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CD8+ T cells even when delivered to the DCs in poorly
replicating vectors and as ultraviolet light and chemically inactivated virions. The potency of DCs in stimulating T cells in vitro reflects both their specialized ability to capture and present antigens and the effects of
other molecules, not present in MHC complexes, that
enhance T cell binding and stimulation.
In vivo evidence for DCs as strong adjuvants. Vaccination
with DCs leads to protective immunity against infections and tumors (8, 9) and, in the case of certain self
antigens, autoimmunity. DCs can be exposed to an
antigen either in vivo, by introducing the antigen
directly, or ex vivo, by pulsing the cells with antigen
while they are in culture and administering them to
genetically matched animals. After antigenic proteins
are given to mice, DCs are found to be the main cells
capturing antigen in an immunogenic form. When
mice are challenged with microbes, DCs also are the
principal cells producing the key protective cytokine
IL-12. Ex vivo–activated DCs can prime recipient animals in an antigen-specific manner, allowing them to
respond to an antigenic challenge within a week. These
DCs migrate to the recipients’ lymph nodes and lodge
in the T cell areas, sites through which lymphocytes
enter the lymph nodes via high endothelial venules
(Figure 1). This movement positions the DCs in a seemingly ideal niche to select antigen-specific T cells when
the latter percolate through the node. Such selection
can be observed directly in situ: Following activation in
contact with DCs, the T cells leave the lymph node,
freeing them to fight infections and tumors. Some also
become memory T cells, a response whose mechanism
remains to be unraveled.
For purposes of vaccine design, it may be most
straightforward to target antigens selectively to DCs
in situ. This has been achieved through the DEC-205
receptor (CD205) (14), which mediates antigen
uptake and processing in DCs. Crucially, induction
of immunity also requires a stimulus that matures
the DEC-205+ DCs. Antigen presentation sets the
stage for antigen-specific T cell recognition, but maturation controls the T cell response. Therefore, vaccines must not only contain the requisite antigens to
initiate protective immunity but also provide stimuli
to promote DC maturation.

Exploiting the adjuvant roles of DCs
To date, the role of DCs in vaccine efficacy has been
studied in detail only in mice receiving DNA vaccinations. Nevertheless, it is already evident that DCs have
several features that could be modulated using appropriately designed vaccines to generate stronger T
cell–mediated immunity. Below, we consider three
aspects of DC biology that are of particular interest in
vaccine development: antigen presentation, DC maturation, and DC mobilization.
Antigen handling and presentation. Vaccine antigens are
not presented directly to the immune system but must
first be captured, processed, and bound to antigen-presenting molecules, typically those of the class I or class
II MHC. Humoral immunity depends on the fact that
1520
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B cells and their antibody products react directly with
native antigens on pathogens or their toxins, thus neutralizing the pathogen or toxin extracellularly, prior to
binding and/or entry into cells. In contrast, T
cell–mediated immunity to intracellular infections
requires recognition of fragmented antigens produced
within infected targets. The fragments are typically
peptides that bind to highly polymorphic class I and
class II products of the MHC and are then displayed on
the cell surface as MHC-peptide complexes (15). Other,
less polymorphic antigen-presenting molecules have
been found, including the CD1 family, which is responsible for the presentation of microbial glycolipids (16),
and the so-called MHC class Ib products, which present formylated bacterial peptides (15).
Despite the fact that DCs can capture and present to
T cells even nonspecific, soluble proteins that prove to
be poorly immunogenic, DC targeting clearly offers a
valuable strategy for vaccination. Quantitative efficiency is one significant benefit of this approach — a
peptide sequence within a protein delivered specifically to DCs is 100–1,000 times more efficient than a peptide given in a nonspecific adjuvant like CFA (14). A
second benefit relates to the quality of the antigen processing (17). For example, by targeting select antigen
uptake receptors on DCs, the vaccine can access their
more efficient antigen processing and presentation
pathways, particularly the exogenous pathway discussed below, which allows proteins and poorly replicating vaccines to load both MHC class I and class II
molecules, as well as CD1.

Figure 1
Lymphocyte and DC circulations. Naive lymphocytes circulate from blood
via high endothelial venules into lymphoid tissues. B cells then move into
follicles while T cells percolate through T cell areas, both eventually leaving the node via efferent lymphatics to return to the blood. Upon antigen
recognition, some activated B and T cells, as well as DCs and follicular
dendritic cells (a distinct cell type that, unlike DCs, retains native antigens as immune complexes), congregate in the follicles to generate the
germinal center reaction for antibody formation. Other activated B and
T cells return to inflammatory sites via the blood or become memory
cells. Some of the latter are termed “effector memory” cells, because they
can rapidly produce cytokines and are positioned in peripheral tissues. In
parallel to the circulation of lymphocytes, DCs move from blood to tissues and then into afferent lymphatics, which bring DCs into the T cell
areas where they eventually die. The plasmacytoid subset of DCs enters
the T cell areas directly from blood; their subsequent fate is unclear.
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Table 1
Challenges in vaccine biology requiring improved control of antigen presentation
Enhance antibody and T cell–mediated immune memory, especially in humans
Improve the quality of the T cell response, e.g., CD4+ Th1 helper and CD8+ killer cells
Achieve mucosal immunity, particularly for sexually transmitted diseases
Design therapeutic as well as preventive vaccines, e.g., against HIV-1 and cancer
Identify vaccines that dampen immunity, e.g., in autoimmune disease

Antigen presentation on MHC class I products, including the
exogenous pathway. The presentation of vaccine antigens
on MHC class I is needed to activate CD8+ CTLs, which
kill infected targets early in the microbial life cycle,
thereby blocking replication and spread of the
pathogen. The classical, “endogenous” pathway for presenting peptides on MHC class I products begins when
DCs or other cells are productively infected, as when
DCs present antigens from influenza and recombinant
vaccinia virus. Following endogenous synthesis within
DCs, microbial proteins are clipped by the proteasome,
and peptide fragments are transported via transporters
for antigen presentation (TAPs) into the rough endoplasmic reticulum (15). There, the resulting peptides are
affixed to the peptide-binding grooves of newly formed
MHC class I products, and the MHC-peptide complexes exit via the Golgi apparatus to reach the surface for
presentation to antigen receptors on T cells (15).
DCs are proving to be quite specialized in their capacities to form MHC class I–peptide complexes, which go
beyond the classical endogenous pathway summarized
above. One specialty is to present viruses that have been
inactivated by ultraviolet light, heat, or chemical treatment, responses not seen with most other cell types.
The inactive viruses retain their capacity to fuse with
the plasma or endocytic vacuole membrane, thereby
delivering some virion proteins into the cytoplasm.
Subsequent efficient processing of incoming virions, or
processing of newly synthesized proteins produced at
low levels, may explain the capacity of DCs to present
inactivated but fusogenic viruses, but this possibility
needs further study.
Another specialty of DCs is to bring about what is
termed “exogenous presentation” or “cross-presentation.” These pathways act, respectively, on proteins
derived from immune complexes or inactivated
microbes, or on antigens originally synthesized in other
cells, which then “cross” to the MHC products of DCs.
In all such cases, antigens depend on selective endocytic uptake receptors to gain access to the cytoplasm of
DCs, after which they likely engage the known DC systems that allow for protein ubiquitination, proteasomal cleavage of antigens, and TAP-mediated peptide
transport. Thus, endocytosed antigens can gain access
to the cytoplasm without the need for a viral envelope
to mediate delivery. The exogenous pathway allows
DCs to present many forms of nonreplicating antigens
on MHC class I and thereby to elicit CD8+ CTLs. Active
infection and biosynthesis do not need to take place in
the DCs (18, 19). A good example is vaccinia virus: This
prototype for successful vaccines is actually presented,
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at least in mice, almost entirely by the exogenous or
cross-presenting routes (20).
Several DC receptors lead to MHC class I–peptide
complex formation via the exogenous pathway. These
include the FcγR, which binds immune complexes and
antibody-coated tumor cells; the integrin αvβ5 and the
phosphatidylserine receptor, which bind dying cells;
and various receptors for heat shock proteins. Subsequent delivery of antigen into the cytosol is postulated to require a transporter that allows macromolecules
to escape the endocytic vacuole. Once in the cytoplasm, proteins may be subject to the newly recognized
heightened capacity of maturing DCs to polyubiquitinylate proteins. Ubiquitin conjugation marks the
proteins for efficient proteasomal processing. It is
anticipated that additional DC specializations will be
found for increasing their efficiency in MHC I–peptide
complex formation.
The exogenous and cross-presentation pathways via
DCs constitute important routes to natural immunity
in many infectious diseases, because DCs can capture
and present antigens from immune complexes or dying
infected cells to elicit CD8+ T cell immunity (18, 19).
These pathways also substantially change how one
approaches the design of vaccines for cell-mediated
immunity. Nonreplicating vaccines, such as protein
subunits and chemically inactivated vaccines, are generally thought to be unable to elicit CD8+ CTLs, which
may be critical for defense against certain chronic intracellular infections and tumors. Subunit and inactive
vaccines lose efficacy, it is thought, because they do not
lead to the new intracellular synthesis of proteins
required for processing in the classical endogenous
pathway to MHC class I. However, the barrier to developing vaccines that engage the class I MHC seems no
longer insurmountable if immunologists can learn to
exploit the exogenous pathway in DCs.
It should be noted that, although many investigators
use the terms “exogenous pathway” and “cross-presentation” to refer exclusively to presentation on MHC
class I, DCs simultaneously present exogenous proteins
and cellular antigens on MHC class I and II. Thus, as
considered below, CD4+ helper T cells can be engaged
to amplify the CD8+ T cell–mediated, MHC class
I–restricted responses initiated by DC presentation.
Antigen presentation on MHC class II products. The MHC
class II pathway, which forms MHC-peptide complexes
to be recognized by CD4+ helper T cells, is particularly
efficient in DCs. To illustrate, when a protein is delivered
to DCs from dead cells, the formation of MHC II–peptide complexes is actually many thousand times more
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efficient than when preprocessed peptides are applied.
DCs have many candidate receptors for dying cells (21),
but active receptors in vivo remain to be identified. Conversely, several DC-restricted uptake receptors are known
(Figure 2) for which natural ligands remain to be identified. One example is the DEC-205 (CD205) uptake
receptor, which traffics in a distinct way through DCs
and greatly enhances antigen presentation relative to
other adsorptive endocytic receptors. DEC-205 can recycle through the acidic late endosomal/lysosomal vacuoles in maturing DCs, compartments that are enriched
for MHC class II molecules and proteinases like the
cathepsins that mediate antigen processing and MHC
class II–peptide complex formation.
These complexes, once formed, are transported to the
DC surface within distinctive nonlysosomal transport
vesicles. The vesicles contain both the MHC-peptide
complexes, recognized by the T cell receptor, and the
CD86 molecules, required to costimulate T cell growth.
Upon arrival at the DC surface, the processed antigen
and CD86 remain coclustered in aggregates that contain so-called tetraspannin membrane proteins. This
situation seems ideal to set up immunologic synapses
between DCs and the T cells that they activate. At this
final mature stage, the DCs silence transcription of
MHC class II products (whose genes are activated by
the transcriptional activator CIITA) and shut down
much of their endocytic activity, while actively presenting antigens captured in the periphery or vaccine
site at lymphoid tissues (Figure 1).

Antigen presentation on CD1
glycolipid- binding molecules
DCs express the known members of the CD1 family of
antigen-presenting molecules, but individual CD1 molecules can be restricted to subsets of DCs. CD1a is typically found on epidermal Langerhans cells in skin,
while CD1b and c are expressed on dermal DCs. CD1
molecules present microbial glycolipids (22), but in
addition, CD1d on monocyte-derived DCs presents the
drug α-galactosylceramide. The CD1d-restricted cells
are called NKT cells. Following recognition of glycosphingolipid on CD1d, NKT cells orchestrate the
production of large amounts of cytokines from several
cell types and have the capacity to act as adjuvants for
T cell–mediated immunity (23). Interestingly, none of
the CD1 molecules have been found on the plasmacytoid subset of DCs discussed below.
DC maturation. In the absence of a perturbation such
as infection or vaccination, most DCs remain at an
immature stage of differentiation. To exploit DCs in
vaccine design, the vaccine must not only provide protective antigens that are captured by DCs; it must also
induce DC maturation.
Immature DCs can capture antigens, but they must
differentiate or mature to become strong inducers of
immunity. DC maturation is the control point that
determines whether an antigen is to become an
immunogen, and it can take place not just as a
response to microbial infections, but also in other
forms of strong T cell–mediated immunity such as
1522
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transplantation reactions, contact allergy, and autoimmunity. There are two well-studied classes of maturation stimuli. One class is provided when the microbe or
vaccine signals DCs through toll-like receptors (TLRs);
a second class is provided by lymphocytes and other
cells (either T, B, NK, NKT, platelets, or mast cells) that
deliver TNF-type signals to the DCs.
Many defined microbial products initiate DC maturation through TLR signaling (24, 25). Cytokine production is triggered quickly, as is also the case with many
other cell types. However, DCs can produce particularly
high levels of immune-enhancing cytokines like IL-12,
IFN-α, and even, in some situations, IL-2. Over longer
periods, DCs mature to become strong adjuvants for T
cell immunity. Expression of specific TLRs can be high
in DCs, particularly TLR9, which responds to microbial
DNA (26), and TLR3, a receptor for double-stranded
RNA. TLRs can respond to particular small molecules,
like specific CpG deoxyoligonucleotide sequences, or to
complex microbial macromolecules like DNA. As discussed below, distinct DC subsets express different complements of TLRs. In terms of signal transduction, TLRs
use the MyD88 adaptor protein to trigger cytokine
release from different cell types (24). However, DC maturation through certain TLRs is also influenced by a
MyD88-independent mechanism (24, 25) that will be
important to identify and manipulate.
TNF family members that stimulate DCs include
TNF itself, Fas ligand (FasL), CD40 ligand (CD40L),
and TRANCE (RANKL). These molecules are
expressed in a membrane-bound form by activated T
cells and signal the corresponding activating subclass

Figure 2
Some specializations of DCs for vaccine capture, MHC-peptide complex
formation, and T cell stimulation. DCs express many adsorptive uptake
receptors whose natural ligands are generally not yet known. For this reason, anti-receptor antibodies are often used experimentally as surrogate
antigens. Several receptors are type II transmembrane proteins with a single external C-type lectin domain found on distinct DC subsets: DC-SIGN
and the asialoglycoprotein receptor on monocyte-derived DCs, BDCA-2
on plasmacytoid cells, and Langerin on Langerhans cells. MMR and
DEC-205 are type I proteins with eight to ten contiguous C-type lectin
domains; these receptors can also be expressed on certain endothelia and
epithelia. Other receptors, such as FcγR, are not DC-restricted but function selectively in DCs to mediate the exogenous pathway for presentation on MHC class I products. Beyond antigen capture, DCs (or particular DC subsets) express high levels of select TLRs and thereby mature in
response to specific microbial stimuli. During maturation, DCs produce
and export high levels of several costimulatory molecules for T cell growth
and differentiation. DC maturation regulates many of the elements
involved in antigen capture and processing.
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of TNF receptors (TNF-Rs). When microbial or vaccine
stimuli mature DCs, CD40 and TRANCE receptor
(TRANCE-R) are induced. As a result, once antigencapturing DCs reach the lymph node (Figure 1), control of DC function can switch from the microbe to
the T cell. Possibly, different maturation stimuli (TLR
signaling via the microbe, for instance, rather than
TNF-R signaling via the T cell) have different consequences for DCs. Full expression of some DC functions, such as IL-12 production, may also require concerted signaling by both of these receptor types.
DC maturation is an intricate differentiation process
whose different components may be under separate
control. Antigen processing and presentation are regulated at several levels, notably through the control of
intracellular proteinase activity. Thus, maturation
diminishes the level of the cysteine protease inhibitor
cystatin C within the endocytic system, permitting
increased catabolism of the invariant chain by cathepsin S, and promoting the binding of antigenic peptides
to MHC class II molecules. The expression of CD40
and other T cell interaction molecules is also enhanced
by maturation. Signaling through CD40, induced by
CD40L on activated T cells, mast cells, and platelets,
leads to the production of DC cytokines and
chemokines and enhances DC migration and survival.
Maturing DCs alter their expression of the costimulatory molecules CD80 and CD86 and of TNF family
members, all of which can influence the extent and
quality of the immune response. Maturing DCs also
reshape their repertoire of chemokine receptors (27).
Mature DCs lose CCR5 and CCR2, which respond to
chemokines in an inflammatory site, but gain CCR7,
which responds to chemokines in the lymphatic vessels
and lymphoid organs. Maturation nicely illustrates the
importance of taking a DC perspective in vaccine
design. By targeting a vaccine to immature DCs and
also maturing the cells, one implements a large spectrum of features (from antigen handling to proper
positioning in vivo to optimal control of the magnitude and quality of the immune response) conducive to
strong antigen-specific immunity.
Many existing vaccines may induce DC maturation,
although their mechanisms can be quite complex.
Some current vaccine vectors — recombinant yeast vaccines and DNA vaccines (28) among them — induce
DCs to become strong stimulators of immunity, probably by directly stimulating TLRs. The attenuated
smallpox and measles vaccines appear to mature DCs
in a different manner. These organisms are both infectious and cytotoxic for DCs and yield infected dead
cells that can then be processed efficiently through the
exogenous pathway in other DCs. Furthermore, perhaps through the release of heat shock proteins, dying
cells can mature the antigen-capturing DCs. Thus, vaccines may produce stronger immunity when they initially kill some DCs.
Effects of DC mobilization. DC mobilization entails
both an increase in the population of these cells and
a change in their migratory properties (27, 29). DC
numbers can be increased tenfold using cytokines like
The Journal of Clinical Investigation
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G-CSF and flt-3L, while DC differentiation from nonproliferating precursors can be influenced by other
hematopoietins (GM-CSF, IL-4) and IFNs. The requisite chemokine receptors for DCs to traffic into a vaccination site may vary, with CCR6 likely responding to
macrophage inflammatory protein 3α (MIP-3α) at
mucosal surfaces, and CCR5 and CCR2 responding to
MIP-1s and monocyte chemoattractant proteins in
other interstitial compartments. For vaccines administered into the skin and muscles, migration to lymph
nodes requires afferent lymphatics (30, 31), but the
DC-lymphatic interaction is still poorly understood.
DCs must also migrate in a directed way to the T cell
areas, responses that are influenced by cysteinyl
leukotrienes and transporters of the multidrug resistance family, as well as the distinct TREM-2 signaling
molecule, each of which acts on the CCR7 lymph node
homing receptor on DCs. Once in the T cell area, DCs
are short-lived, apparently dying within a few days. Their
lifespans can be prolonged through membrane bound
TNFs on the T cell, e.g., CD40L and TRANCE (RANKL).
In summary, we propose that vaccine efficacy or
immunogenicity can be improved by altering DC functions at three levels: by enhancing vaccine capture and
processing, by promoting DC maturation, and by
increasing DC numbers by stimulating DC replication,
survival, and migration, to the lymph nodes.

Other endpoints in the immune response
that can be achieved via DCs
Improved cell-mediated responses and T cell memory.Antigen-primed DCs rapidly prime an individual to form
IFN-γ–producing or Th1CD4+ helper cells. When DC
maturation is blocked, IL-4– and IL-5–producing Th2
helper cells seem to be induced, resulting in less efficient T cell–mediated immunity and memory, as well
as the production of undesirable antibody subclasses
— notably IgEs, which mediate allergy. Th1 helpers are
especially critical in activating macrophages to resist
intracellular bacteria and protozoa, and they are also
the most effective form of helper for CD8+ CTL resistance to experimental viral infections and tumors.
CD4+ Th1 cells additionally render DCs resistant to
killing by CD8+ CTLs and directly lyse important
MHC class II–expressing infected cells through a FasLdependent (rather than perforin/granzyme–dependent) mechanism. The induction of Th1 cells is often
ascribed to IL-12, but mature DCs can lose high-level
IL-12 production while maintaining their ability to
induce strong CD4+ Th1 and CD8+ CTL responses in
vivo, possibly through other cytokines or special B7
and TNF family members.
When DCs directly stimulate CD8+ CTLs in humans,
the T cells can kill targets in the presence of lower doses
of peptide; in this way, the functional affinity of the
CD8+ T cell is improved. A recent intriguing mechanism for this is that antigen-reactive T cells somehow
remove MHC-peptide from the DCs, favoring selection
of the more competitive, higher-affinity T cells. Importantly, DCs induce T cell memory for both high-affinity CD8+ and Th1 CD4+ responses.
June 2002

|

Volume 109

|

Number 12

1523

Generation of antibody-forming B cells. Classically, DCs
enhance antibody formation by promoting the formation of antigen-specific CD4+ helper T cells, which
induce antigen-specific B cells to proliferate and make
antibody. In situ, IFN-α enhances T-dependent antibody formation, isotype switching, and memory. To
obtain this result, DCs are the only cells that need to
express the requisite type I IFN receptors. DCs can have
direct effects on B cells that greatly enhance Ig secretion and isotype switching, including the production
of the IgA subclass of antibodies, which contribute to
mucosal immunity. Recently, DCs have been pulsed ex
vivo with cell wall constituents from Streptococcus pneumoniae. When the DCs are reinfused into genetically
matched mice, strong T-dependent B cell responses are
induced to microbial proteins and capsular polysaccharides. This requires IL-6 production by the DCs and
quite possibly a ménage à trois wherein B and T cells
respond to native and processed antigens being presented on the same DC or DC subset. Consequently, if
vaccines are delivered to the appropriate DCs, combined B cell and T cell immunity can ensue, an important consideration in the context of HIV-1 and other
chronic infections.
Implementation of mucosal immunity. Vaccines are lacking for many sexually transmitted diseases. Strong T
cell immunity and IgA antibodies may be required to
provide protection from HIV-1, Epstein-Barr, herpes
simplex, and human papilloma viruses. DCs are located beneath the antigen-transporting epithelium (M
cells) (32) of mucosal lymphoid organs, and they may
extend their processes through standard, lining epithelia to capture antigens. Access of vaccines to mucosal
DCs should prove valuable for inducing mucosal
immunity. However, maturation is again likely to be
needed. Some mucosal DCs in the steady state produce
IL-10 and may induce regulatory or immunosuppressive T cells, as discussed below. The latter would compromise vaccine efficacy.

Newly appreciated features of DCs
relevant to vaccination
DC-induced tolerance. The immune-enhancing or adjuvant roles of DCs are exerted in two phases. In the first
immediate or innate phase, DCs capture the antigen,
begin to mature in response to stimuli, particularly
microbial components, and produce cytokines and
chemokines that mobilize and differentiate other cells,
including NK cells. In the slower (adaptive) phase, DCs
stimulate several components of the T cell response:
clonal expansion; differentiation, specifically into Th1
helper or killer cells; and memory. Much of current
effort by DC biologists focuses on a different effect of
these cells, namely their capacity, when in the immature state, to induce antigen-specific unresponsiveness
or tolerance following antigen capture.
DCs in the steady state are immature and can silence
immunity in an antigen-specific manner through two
recently identified mechanisms (33). Here, the “steady
state” refers to the absence of acute inflammation and
infection, with the latter providing stimuli that mature
1524
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DCs via TLRs and TNF-Rs. One tolerance mechanism
is exerted by DCs bearing the DEC-205 receptor in the
lymph nodes. When antigen is targeted to these DCs in
the absence of a maturation stimulus, interacting T
cells proliferate but are soon deleted. Effector functions
(IFN-γ secretion) and memory therefore do not develop, and the animal becomes tolerant to rechallenge
with the peptide in a strong adjuvant (14). In contrast,
chronic stimulation of DCs may predispose to the
development of autoimmunity, including lupus erythematosus. A second tolerance mechanism involves
the induction by certain immature DCs of IL-10–producing T cells, which in turn can silence other effector
T cells. The tolerogenic roles of DCs could compromise
vaccine efficacy. Conversely, the capacity to induce regulatory T cells may be useful in the design of a new
class of vaccines for suppressing immunity in autoimmune diseases, allergy, and transplantation.
Contributions of DC subsets to innate immunity. There are
many different forms of DCs in situ. These comprise
the Langerhans cells in the skin and other epithelia
and various DC precursors in blood, including monocytes and plasmacytoid DCs. Many DCs move from
blood to tissues to lymph and then to the lymph node,
but plasmacytoid DCs can move from blood directly
into the lymph node via high endothelial venules, presumably by virtue of their CD62L expression (Figure
1). A hallmark of the plasmacytoid DC is the capacity
to produce prodigious levels of IFN-α upon challenge
with many viruses.
The raison d’être for these DC subsets has been a
mystery, but some recent findings provide new perspectives. DC subsets vary in their expression of
TLRs and therefore respond to different microbial
stimuli. For example, CD11c+ CD14– cells in blood
are the principal expressers of TLR3, a receptor for
double-stranded viral RNA, whereas plasmacytoid
cells are the main cell in blood expressing TLR9, the
receptor for bacterial DNA and specific CpG deoxyoligonucleotides (26). Furthermore, distinct DC subsets can produce large amounts of individual
cytokines (IL-12, TNF, IFN-α) in response to TLR
signaling. This, in turn, may influence the kinds of
lymphocytes (Th1 helpers, CD8 + CTLs) that are
expanded by the antigen-presenting DCs. Importantly, because DC subsets also express different
endocytic receptors, it may be possible to design
selective vaccines targeting Langerhans cells, plasmacytoid DCs, or monocyte-derived DCs (Figure 2).
As immune responses to specific pathogen-associated antigens are elucidated, it may prove important
to target vaccines through the appropriate DC subset to take advantage of their distinct pathways for
antigen uptake, maturation, and cytokine release.

DCs in the response to DNA vaccines
DNA vaccines are now showing promise in priming for
resistance to simian immunodeficiency virus. At face
value, the efficacy of DNA vaccines is perplexing, since
the vaccine proteins are expressed primarily within skin
or muscle cells, which are weak antigen-presenting cells
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for inducing immunity. However, successful DNA vaccination may involve DCs (28). A few DCs may be
directly transfected with the vaccine and be responsible
for immune priming. DCs may also capture antigens
expressed in other cells that die following transfection
and protein expression. Importantly, DNA itself activates many other DCs that are not transfected, most
likely via TLR9 (26). Unfortunately, the requisite DNA
receptors (and their CpG deoxyoligonucleotide mimics) may be expressed in different DC types in primates
and in rodents. In human blood, for example, TLR9 is
primarily expressed by the plasmacytoid DC, while, in
mice, other subsets of DCs respond to DNA and CpG
oligonucleotides. Therefore it remains challenging for
DNA vaccines to direct the maturation of human DCs.
This maturation can be regarded as a universal platform for vaccine efficacy.
The boosting of DNA-vaccinated individuals with
viral vectors may also exploit DCs — again through
several mechanisms. The vectors may directly infect
DCs or be presented by the exogenous pathway. Some
viral vectors may kill infected DCs, leading to uptake
and maturation by other DCs as discussed above. In
spite of these possibilities, there are few studies of DC
function in the setting of DNA prime-viral vector
boost vaccination in animals and, as a result, little
direct information on whether DCs could be exploited to a greater extent.
Ex vivo–derived DCs in cancer vaccines. A new field has
emerged in the setting of cancer immunotherapy (see
Yu and Restifo, this Perspective series, ref. 13). Human
DCs are generated ex vivo from progenitors, charged
with antigens from the tumor, and then reinfused to
boost a patient’s immunity in an antigen-specific manner (10–12). Beyond the goal of developing new therapeutic vaccines that prevent the initial development or
recurrence of tumors, the ex vivo DC approach provides an opportunity to investigate many pertinent features of human DCs as natural adjuvants. For example,
the way to load DCs with a large spectrum of antigens
can be monitored and optimized, the functions of distinct DC subsets can be assessed, and the maturation
status of the DCs can be manipulated.
The immunologic impact of DC interactions with specific
pathogens. Despite the evident promise of DCs for vaccination, it is important not to overlook the immuneevasive capacities of individual pathogens, many of
which can directly disrupt components of DC function. HIV-1 and measles can be cytopathic, particularly following syncytium formation between DCs and T
cells. Herpes simplex, cytomegalovirus, lymphocytic
choriomeningitis virus, and tumors can block DC
functions, including maturation.
The premise of vaccine design is that strong immunity will be able to block the pathogen before it can
significantly compromise immunity, even at the level
of DCs. Nevertheless, two disquieting aspects of this
interaction have come to light, especially in the setting
of HIV-1. First, DCs can act like a Trojan horse to
transport HIV-1 to T cell sites for replication. First,
The DC-restricted lectin DC-SIGN, which is normally
The Journal of Clinical Investigation
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used by DCs to bind ICAM-3 on resting T cells, also
binds HIV-1 and enhances its infectivity for T cells following initial uptake into DCs (34). Second, the large
amounts of HIV-1 produced during chronic HIV-1
infection are proposed to exploit the normal tolerizing
role of immature DCs (33), and to induce T cell deletion and regulatory T cell formation. HIV-1 virions
bind several receptors on the tolerizing, immature
form of DCs, including DC-SIGN, CD4, CCR5. In the
difficult case of HIV-1, DCs therefore occupy both
fronts of vaccine biology, guiding the offense of the
pathogen and bolstering the defense of the host. Thus,
pathogen interactions with DCs can present a formidable challenge to the development of safe vaccines
that target these cells.

Conclusions
Vaccine design extends beyond the identification of
antigens. It needs to harness the immunologic mechanisms that lead to strong and lasting immunity. In
many instances, particularly the induction of T
cell–mediated immunity, these mechanisms are controlled by antigen-presenting DCs, potent stimulators
of specific T cell immunity, in tissue culture, in model
organisms, and in humans. DCs in essence act as
nature’s adjuvants to generate immune resistance.
We have outlined three areas of DC biology that
might be exploited to improve vaccine efficacy. First,
DCs have select receptors for enhancing antigen uptake
and processing; these could be targeted to improve the
presentation of vaccine antigens to both CD4+ Th1
helper cells and CD8+ CTLs. Second, DCs undergo a
process of terminal differentiation or maturation, typically in response to signaling via TLRs; vaccine-based
stimulation of DC maturation is required in addition
to antigen capture for DCs to elicit strong T cell immunity. Third, the numbers and migration of DCs in situ
can be controlled to improve the selection of particular
antigen-responsive lymphocytes. Several newly recognized DC functions pertinent to vaccine design are
emerging. DCs or certain DC subsets exert innate functions, such as the production of large amounts of
immune-enhancing cytokines. DCs also influence antibody production, control mucosal immunity, and, in
the absence of maturation, induce antigen-specific
silencing or tolerance. Ironically, because many of the
pathogens for which vaccines are desired, especially
HIV-1, have the capacity to exploit these cells during
their replication or as means to evade immune defenses, DCs contribute to the pathogenesis and protective
fronts of vaccine biology.
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